CellCept

Mycophenolate mofetil (CellCept) inhibits DNA and RNA synthesis and has been shown to have a specific lymphocyte antiproliferative effect. Although not FDA approved for this indication, oral mycophenolate mofetil appears effective in the treatment of moderate to severe plaque psoriasis. The usual dose is 500 mg orally four times a day, up to a maximum of 4 g/day. Common adverse effects include GI toxicity (diarrhea, nausea, vomiting), hematologic effects (anemia, neutropenia, thrombocytopenia), and viral and bacterial infections. Lymphoproliferative disease or lymphoma has been reported. 

Powder for oral suspension 200 mg/mL (constituted, as CellCept mofetil) (Rx) (Roche)... 

Mycophenolate mofetil (MMF, CellCept) is an ester prodrug of mycophenolic acid (MPA), a Penicillium-de-rived immunosuppressive agent (see Chapter 57) that blocks de novo purine synthesis by noncompetitively inhibiting the enzyme inosine monophosphate dehydrogenase. MPA preferentially suppresses the proliferation of cells, such as T and B lymphocytes, that lack the purine salvage pathway and must synthesize de novo... 

Prevention of renal transplant refection PO, IV (Cellcept) Ig twice a day, PO (Myfortic) 720 mg twice a day. 

Parenteral 5 mg/5 mL ampule for injection Mycophenolate mofetil (CellCept, Myfortic)... 

Formulation 250 mg capsules supplied in bottles of fOO and 500 500 mg tablets in bottles of 100 and 500 CellCept intravenous 20 ml, sterile vial containing 500 mg mycophenolate mofetil... 

Clinical Use. Mycophenolate mofetil (CellCept) is primarily used to prevent or treat organ rejection following cardiac and renal transplantation. This drug is typically combined with other immunosuppressants (cyclosporine, glucocorticoids) to provide optimal immunosuppression in patients receiving these transplant types.39,40,70 Mycophenolate mofetil may also be useful in suppressing the immune response associated with autoimmune conditions such as systemic lupus erythematosus.2... 

Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. Transplant Proc 1997 29(1—2) 334—336. 

CellCept Mycophenolate mofetil Combantrin Pyrantel pamoate... 

SLE appears to be steroid responsive only in the early coiu se of the disease. Optic atrophy occiu s in untreated cases, with the development of permanent visual field defects. Therapy includes high-dose intravenous methyl-prednisolone, oral prednisone, or steroid-sparing medications such as mycophenolate mofetil (CellCept). A rheumatology referral is also advised. 

---